ArticleJournal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance2021
Multi-parametric cardiovascular magnetic resonance with regadenoson stress perfusion is safe following pediatric heart transplantation and identifies history of rejection and cardiac allograft vasculopathy.
Article in Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 27 citations in OpenAlex.
- Advanced Cardiac Imaging Techniques for Detection of Myocardial Ischemia in Children with Coronary Artery Abnormalities.Cardiology and therapy · 2026Review
- Non-invasive detection of acute cell-mediated graft rejection in paediatric heart transplant recipients: The role of cardiovascular magnetic resonance.International journal of cardiology. Congenital heart disease · 2026Article
- Reduced regadenoson dose using heart rate-targeted titration in paediatric stress perfusion CMR.European heart journal. Imaging methods and practice · 2026Article
- Abnormal Cardiac Magnetic Resonance Imaging Mapping Parameters in Pediatric Heart Transplant Patients with Elevated Donor-Derived Cell Free DNA.Pediatric cardiology · 2026Article
- Multimodality Approach to Coronary Ischemic Testing in Pediatric Patients: A Scientific Statement From the American Heart Association.Journal of the American Heart Association · 2026Review
- Pediatric Use of Regadenoson for Stress Cardiovascular Magnetic Resonance Imaging: A Systematic Literature Review.Pediatric cardiology · 2026Review
- Cardiac Magnetic Resonance Imaging in Pediatric Heart Transplant Recipients: Correlation with Cardiopulmonary Exercise Testing.Pediatric cardiology · 2025Article
- Cardiac magnetic resonance imaging assessment of myocardial disease in children and adolescents.Cardiovascular diagnosis and therapy · 2025Review
- Multiparametric quantitative structural and functional cardiac MRI in orthotopic heart transplant recipients with cardiac allograft vasculopathy.The international journal of cardiovascular imaging · 2025Article
- Longitudinal Assessment of T1 Mapping Trends Disease in Pediatric Patients With Heart Transplant.Journal of the American Heart Association · 2024Article
- Importance of Cardiovascular Magnetic Resonance Applied to Congenital Heart Diseases in Pediatric Age: A Narrative Review.Children (Basel, Switzerland) · 2024Review
- Cardiac magnetic resonance assessment of acute rejection and cardiac allograft vasculopathy in pediatric heart transplant.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2024Article
- Late-gadolinium enhancement is common in older pediatric heart transplant recipients and is associated with lower ejection fraction.Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance · 2023Article
- Left Ventricular Physiology and Ventricular-Vascular Interactions in Young Patients After Heart Transplantation.Journal of the American Heart Association · 2023Article
- Multiparametric cardiovascular magnetic resonance characteristics and dynamic changes in asymptomatic heart-transplanted patients.European radiology · 2023Article
- Coronary allograft vasculopathy in post-heart transplant patients: pathogenesis and role of cardiac computed tomography in diagnosis-a comprehensive review.Annals of medicine and surgery (2012) · 2023Article
- Multicenter research priorities in pediatric CMR: results of a collaborative wiki survey.Scientific reports · 2023Article
- The Use of Stress Cardiovascular Imaging in Pediatric Population.Children (Basel, Switzerland) · 2023Review
- Early Postoperative Cardiac Complications Following Heart Transplantation:.Galen medical journal · 2023Article
- Native T1 mapping detects both acute clinical rejection and graft dysfunction in pediatric heart transplant patients.Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundThe progressive risk of graft failure in pediatric heart transplantation (PHT) necessitates close surveillance for rejection and coronary allograft vasculopathy (CAV). The current gold standard of surveillance via invasive coronary angiography is costly, imperfect and associated with complications. Our goal was to assess the safety and feasibility of a comprehensive multi-parametric CMR protocol with regadenoson stress perfusion in PHT and evaluate for associations with clinical history of rejection and CAV.
methodsWe performed a retrospective review of 26 PHT recipients who underwent stress CMR with tissue characterization and compared with 18 age-matched healthy controls. CMR protocol included myocardial T2, T1 and extracellular volume (ECV) mapping, late gadolinium enhancement (LGE), qualitative and semi-quantitative stress perfusion (myocardial perfusion reserve index; MPRI) and strain imaging. Clinical, demographics, rejection score and CAV history were recorded and correlated with CMR parameters.
resultsMean age at transplant was 9.3 ± 5.5 years and median duration since transplant was 5.1 years (IQR 7.5 years). One patient had active rejection at the time of CMR, 11/26 (42%) had CAV 1 and 1/26 (4%) had CAV 2. Biventricular volumes were smaller and cardiac output higher in PHT vs. healthy controls. Global T1 (1053 ± 42 ms vs 986 ± 42 ms; p < 0.001) and ECV (26.5 ± 4.0% vs 24.0 ± 2.7%; p = 0.017) were higher in PHT compared to helathy controls. Significant relationships between changes in myocardial tissue structure and function were noted in PHT: increased T2 correlated with reduced LVEF (r = - 0.57, p = 0.005), reduced global circumferential strain (r = - 0.73, p < 0.001) and reduced global longitudinal strain (r = - 0.49, p = 0.03). In addition, significant relationships were noted between higher rejection score and global T1 (r = 0.38, p = 0.05), T2 (r = 0.39, p = 0.058) and ECV (r = 0.68, p < 0.001). The presence of even low-grade CAV was associated with higher global T1, global ECV and maximum segmental T2. No major side effects were noted with stress testing. MPRI was analyzed with good interobserver reliability and was lower in PHT compared to healthy controls (0.69 ± - 0.21 vs 0.94 ± 0.22; p < 0.001).
conclusionIn a PHT population with low incidence of rejection or high-grade CAV, CMR demonstrates important differences in myocardial structure, function and perfusion compared to age-matched healthy controls. Regadenoson stress perfusion CMR could be safely and reliably performed. Increasing T2 values were associated with worsening left ventricular function and increasing T1/ECV values were associated with rejection history and low-grade CAV. These findings warrant larger prospective studies to further define the role of CMR in PHT graft surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.